| [1] |
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy [J]. Eur Heart J，2018，39(34)：3165-3241.
|
| [2] |
Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy [J]. Eur J Heart Fail，2019，21(7)：827-843.
|
| [3] |
中华医学会心血管病学分会，中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南 [J]. 临床心血管病杂志，2018，34(5)：421-434.
|
| [4] |
Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review [J]. JAMA, 2000，283(9): 1183-1188.
|
| [5] |
Isogai T, Kamiya CA. Worldwide Incidence of Peripartum Cardiomyopathy and Overall Maternal Mortality [J]. Int Heart J, 2019, 60(3)：503-511.
|
| [6] |
Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital [J]. Ethn Dis，2007，17(2)：228-233.
|
| [7] |
Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution [J]. Mayo Clin Proc, 2005, 80(12)：1602-1606.
|
| [8] |
Kuklina EV, Callaghan WM. Cardiomyopathy and other myocardial disorders among hospitalizations for pregnancy in the United States: 2004-2006 [J]. Obstet Gynecol，2010，115(1)：93-100.
|
| [9] |
Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study[J]. J Am Heart Assoc，2014，3(3)：1-13.
|
| [10] |
Gentry MB, Dias JK, Luis A, et al. African-American women have a higher risk for developing peripartum cardiomyopathy [J]. J Am Coll Cardiol, 2010，55(7): 654-659.
|
| [11] |
岳晓辉，刘楠，薛晓艳. 我国围产期心肌病流行病学特点及转归荟萃分析 [J]. 中国妇产科临床杂志，2011，12(5)：359-363.
|
| [12] |
Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis [J]. Trends Cardiovasc Med，2015，25(6)：499-504.
|
| [13] |
Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy [J]. Lancet, 2006, 368 (9536): 687-693.
|
| [14] |
Cunningham FG, Byrne JJ, Nelson DB. Peripartum Cardiomyopathy [J]. Obstet Gynecol, 2019，133(1)：167-179.
|
| [15] |
Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies [J]. N Engl J Med，2016，374(3)：233-241.
|
| [16] |
Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy [J]. Cell, 2007，128(3): 589-600.
|
| [17] |
Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study [J]. Eur Heart J，2017，38(35)：2671-2679.
|
| [18] |
Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy [J]. J Clin Invest, 2013, 123(5): 2143-2154.
|
| [19] |
Stapel B, Kohlhaas M, Ricke-Hoch M, et al. Low STAT3 expression sensitizes to toxic effects of beta-adrenergic receptor stimulation in peripartum cardiomyopathy [J]. Eur Heart J, 2017，38(5)：349-361.
|
| [20] |
车千秋，王琼英，梁宇博，等. 围产期心肌病的病因学研究进展[J]. 中华心力衰竭和心肌病杂志，2019，3(1)：41-44.
|
| [21] |
Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy [J]. Nature, 2012, 485(7398)：333-338.
|
| [22] |
Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study [J]. JACC Heart Fail，2016，4(5)：380-388.
|
| [23] |
Goland S, Weinstein JM, Zalik A, et al. Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients [J]. Circ Heart Fail, 2016，9(11)：1-7.
|
| [24] |
Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management[J]. J Am Coll Cardiol, 2011, 58(7): 659-670.
|
| [25] |
赵敏琦. 围产期心肌病的诊断与治疗新进展 [J]. 中国实用妇科与产科杂志，2013，29(5)：386-389.
|
| [26] |
Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy [J]. J Am Coll Cardiol，2014，64(15)：1629-1636.
|
| [27] |
Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association [J]. Circulation, 2016，134(23)：e535-e578.
|
| [28] |
Ezekowitz JA, O′Meara E, Mcdonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure[J]. Can J Cardiol, 2017，33(11)：1342-1433.
|
| [29] |
Hoevelmann J, Viljoen CA, Manning K, et al. The prognostic significance of the 12-lead ECG in peripartum cardiomyopathy[J]. Int J Cardiol，2019，276：177-184.
|
| [30] |
Arany Z, Elkayam U. Peripartum Cardiomyopathy [J]. Circulation, 2016，133(14)：1397-1409.
|
| [31] |
Arrigo M, Blet A, Mebazaa A. Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD [J]. Eur Heart J，2017，38(35)：2680-2682.
|
| [32] |
Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study [J]. Circulation，2010，121(13)：1465-1473.
|
| [33] |
Haghikia A, Podewski E, Berliner D, et al. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy [J]. Clin Res Cardiol, 2015，104(11)：911-917.
|
| [34] |
刘燕燕，冯玲. 围产期心肌病诊治[J]. 中国实用妇科与产科杂志，2019, 35(11)：1224-1228.
|
| [35] |
Beadle RM, Williams LK, Kuehl M, et al. Improvement in cardiac energetics by perhexiline in heart failure due to dilated cardiomyopathy [J]. JACC Heart Fail, 2015, 3(3)：202-211.
|
| [36] |
Honigberg MC, Givertz MM. Peripartum cardiomyopathy [J]. BMJ, 2019, 364: 1-14.
|
| [37] |
Elkayam U, Goland S, Pieper PG, et al. High-Risk Cardiac Disease in Pregnancy: Part Ⅱ [J]. J Am Coll Cardiol, 2016，68(5)：502-516.
|